FILONEX:边缘供肺EVLP联合血液透析滤过的前瞻性随机对照初步安全性研究
FILONEX为单中心前瞻性随机对照初步研究,将30例边缘供肺1:1随机分组,在6小时无细胞常温EVLP中于第1小时后加入血液透析滤过(HDF)。结果显示HDF组电解质、乳酸和pH仅维持在生理范围,受体接受率80%对47%,ICU入室时PGD 3级为25%对57%(p=0.093),72小时两组均无PGD 3级;结论为HDF整合入EVLP回路可行且安全。
要点
- 边缘供肺EVLP中加入HDF在6小时灌注内可行且安全
- HDF组电解质、乳酸和pH维持在生理范围,对照组未维持
- 接受率HDF组80%对对照组47%,PGD 3级差异未达统计学意义
核心结论
- 在6小时EVLP灌注中将HDF整合入回路是可行且安全的,未对EVLP性能或肺移植后短期结局产生不良影响。
研究设计与样本
- 单中心前瞻性随机对照初步研究,共纳入30例边缘供肺,于获取时按1:1随机分组。
- 所有供肺接受6小时无细胞常温EVLP,治疗组在1小时后于EVLP回路中加入HDF,对照组仅EVLP无辅助治疗。
主要发现
- 供受体特征两组相似。
- 电解质、乳酸和pH仅在治疗组维持在生理范围。
- 接受率对照组47%(n=7),治疗组80%(n=12)。
- ICU入室时PGD 3级对照组57%(n=4),治疗组25%(n=3),p=0.093;72小时两组均无PGD 3级。
- 术后VA-ECMO延长对照组3例(43%),治疗组1例(8%),p=0.075;机械通气时间、ICU停留、住院时间和短期死亡率两组相当。
临床怎么用
- 对于边缘供肺,可考虑在EVLP回路中加入HDF以维持灌注液生理状态,但需注意本研究为初步安全性探索。
局限性
- 单中心初步研究,样本量小(30例),部分结局比较未达统计学显著性,需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The lack of physiologic clearance mechanisms during ex vivo lung perfusion (EVLP) may lead to electrolyte imbalances, accumulation of toxic metabolites and disturbances in starling forces. The integration of dialysis may help to maintain perfusate physiology. The FILONEX trial investigates the feasibility and safety of this strategy. METHODS: This single-center prospective randomized controlled study included 30 marginal donor lungs randomized 1:1 at procurement. Normothermic acellular EVLP was performed for six hours. After one hour, hemodiafiltration (HDF) was added to the EVLP circuit in the treatment group, whereas the control group received EVLP without any adjunct therapy. Primary endpoints were suitability for transplantation after EVLP, and primary graft dysfunction (PGD) grade 3 at 72 h after transplantation. RESULTS: Donor and recipient characteristics were similar between the groups. Electrolyte levels, lactate and pH remained within physiological ranges only in the treatment group. Acceptance rate was 47% (n=7) in the control and 80% (n=12) in the treatment group. PGD grade 3 at ICU admission was 57% (n=4) in the control and 25% (n=3) in the treatment group (p=0.093). There were no cases of PGD grade 3 at 72 h in either group. In 3 (43%) control patients, VA-ECMO was prolonged postoperatively compared to 1 (8%) patient in the treatment group (p=0.075). Length of mechanical ventilation, ICU stay, hospital stay and short-term mortality were comparable among the groups. CONCLUSION: This prospective randomized trial demonstrates that integrating HDF into the EVLP circuit is feasible and safe during six hours of perfusion, without adverse effects on EVLP performance or short-term outcomes after lung transplantation.
引用
- Boehm PM, Auner S, Berezhinskiy O, et al. FILONEX - A prospective, randomized controlled pilot safety study evaluating the addition of hemodiafiltration to EVLP in marginal donor lungs. J Heart Lung Transplant. 2026. PMID: 42031081. doi:10.1016/j.healun.2026.04.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。